2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK Cytoskeleton Cell Cycle/DNA Damage
  3. Antibody-Drug Conjugates (ADCs) c-Met/HGFR Microtubule/Tubulin
  4. Telisotuzumab vedotin

Telisotuzumab vedotin  (Synonyms: ABBV-399)

Cat. No.: HY-141601 Pureza: 99.26%
COA
SDS
Instrucciones de manejo Technical Support

Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1714088-51-3

Tamaño Precio Stock Cantidad
1 mg En stock
5 mg En stock
10 mg En stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 2 publication(s) in Google Scholar

Telisotuzumab vedotin Related Antibodies

Top Publications Citing Use of Products
In Vivo Efficacy Study
In Vivo Imaging

    Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688.

    Comparison of tumor suppression between B6ADC and the combination of “marketed TROP2ADC (SG) and marketed c-MetADC (Telisotuzumab vedotin, 10 nmol/kg)” in SPC-A1 tumor-bearing mice (initial tumor volume: 600 mm3) (n = 5∼7/group).

    Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688.

    Bioluminescence imaging of mice with orthotopic pancreatic tumors treated with B6ADC or the combination of "SG and Telisotuzumab vedotin (10 nmol/kg)" for 28 days (n = 4/group).

    Telisotuzumab vedotin purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Apr 21;7(4):102688.

    Survival curves of mice treated with B6ADC or SG+Telisotuzumab vedotin (10 nmol/kg). Survival analysis was performed using the Kaplan-Meier method, and statistical significance was determined by the log rank (Mantel-Cox) test.

    • Actividad biológica

    • Pureza y Documentación

    • Referencias

    • Revisión del cliente

    Descripciòn

    Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research[1][2][3].

    In Vitro

    ABBV-399 demonstrates potent cytotoxicity that is dependent on a threshold level of target expression and is not reliant on inhibiting MET signaling in tumor cell lines with high c-Met expression or MET amplification[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Telisotuzumab vedotin Related Antibodies
    In Vivo

    ABBV-399 effectively inhibits tumor growth and overcomes resistance to small molecule MET inhibitors in xenograft models resistant to other c-Met inhibitors[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Ensayo clínico
    Peso molecular

    145000 (average)

    No. CAS
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Telisotuzumab vedotin]
    Envío

    Shipping with dry ice.
    Almacenamiento

    -80°C, protect from light
    Pureza y Documentación

    Purity: 99.81%

    SDS (251 KB)

    COA (231 KB) Others (381 KB) SEC-HPLC (370 KB)

    Instrucciones de manejo (2659 KB)
    Referencias
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Telisotuzumab vedotin Related Classifications

    • Calculadora de molaridad

    • Calculadora de dilución

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Telisotuzumab vedotin1714088-51-3ABBV-399ABBV399ABBV 399Antibody-Drug Conjugates (ADCs)c-Met/HGFRMicrotubule/TubulinAntibody-Drug ConjugatesNon-Small Cell Lung CancertumorADCInhibitorinhibitorinhibit

    Productos vistos recientemente:

    Consulta en línea

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Requested Quantity *

    Nombre del solicitante *

    		 

    Saludo

    Direcciòn del E-mail *

    		 

    Número de teléfono *

    Department

    		 

    Nombre de la Organizaciòn *

    City

    Provincia

    Country or Region *

    		      

    Observaciones

    Consulta para venta a granel

    Inquiry Information

    Nombre del producto:
    Telisotuzumab vedotin
    Cat. No.:
    HY-141601
    Cantidad:
    MCE Japan Authorized Agent:

    Revisión del cliente

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Lot #

    Nombre del solicitante *

    		 

    Direcciòn del E-mail *

    Número de teléfono

    		 

    Department *

    Nombre de la Organizaciòn *

    		 

    Country or Region *

    Observaciones

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.